EP1030684A4 - Anticorps modifies a capacite amelioree de declenchement d'une reponse anti-idiotype - Google Patents

Anticorps modifies a capacite amelioree de declenchement d'une reponse anti-idiotype

Info

Publication number
EP1030684A4
EP1030684A4 EP98958584A EP98958584A EP1030684A4 EP 1030684 A4 EP1030684 A4 EP 1030684A4 EP 98958584 A EP98958584 A EP 98958584A EP 98958584 A EP98958584 A EP 98958584A EP 1030684 A4 EP1030684 A4 EP 1030684A4
Authority
EP
European Patent Office
Prior art keywords
elicit
modified antibodies
enhanced ability
idiotype response
idiotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98958584A
Other languages
German (de)
English (en)
Other versions
EP1030684A1 (fr
Inventor
Ronald M Burch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of EP1030684A1 publication Critical patent/EP1030684A1/fr
Publication of EP1030684A4 publication Critical patent/EP1030684A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP98958584A 1997-11-14 1998-11-13 Anticorps modifies a capacite amelioree de declenchement d'une reponse anti-idiotype Withdrawn EP1030684A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6571697P 1997-11-14 1997-11-14
US65716P 1997-11-14
US8140398P 1998-04-10 1998-04-10
US81403P 1998-04-10
PCT/US1998/024303 WO1999025379A1 (fr) 1997-11-14 1998-11-13 Anticorps modifies a capacite amelioree de declenchement d'une reponse anti-idiotype

Publications (2)

Publication Number Publication Date
EP1030684A1 EP1030684A1 (fr) 2000-08-30
EP1030684A4 true EP1030684A4 (fr) 2004-09-15

Family

ID=26745908

Family Applications (2)

Application Number Title Priority Date Filing Date
EP98958583A Withdrawn EP1032420A4 (fr) 1997-11-14 1998-11-13 Molecules d'immunoglobuline a partie variable de synthese et a specificite modifiee
EP98958584A Withdrawn EP1030684A4 (fr) 1997-11-14 1998-11-13 Anticorps modifies a capacite amelioree de declenchement d'une reponse anti-idiotype

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP98958583A Withdrawn EP1032420A4 (fr) 1997-11-14 1998-11-13 Molecules d'immunoglobuline a partie variable de synthese et a specificite modifiee

Country Status (9)

Country Link
EP (2) EP1032420A4 (fr)
JP (2) JP2001526021A (fr)
KR (2) KR20010015818A (fr)
CN (2) CN1294517A (fr)
AU (2) AU763029B2 (fr)
BR (2) BR9815580A (fr)
CA (2) CA2309990A1 (fr)
IL (2) IL136113A0 (fr)
WO (2) WO1999025379A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029443A1 (fr) * 1998-11-13 2000-05-25 Euro-Celtique, S.A. Vaccins contraceptifs contenant un anticorps
ES2447115T3 (es) * 1999-10-11 2014-03-11 Institut Pasteur Vectores para la preparación de composiciones inmunoterapéuticas
WO2001088159A2 (fr) * 2000-05-16 2001-11-22 Euro-Celtique S.A. Anticorps synthetique cd28 servant a la modulation de responses immunitaires
AU2002234001B2 (en) 2000-12-05 2008-05-01 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040143101A1 (en) * 2001-04-02 2004-07-22 Soltis Daniel A. Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
AU2002365926A1 (en) * 2001-10-25 2003-09-02 Euro-Celtique S.A. Compositions and methods directed to anthrax toxin
EP1499346B1 (fr) * 2002-04-09 2008-01-02 The Curators Of The University Of Missouri Traitement du diabete de type 1 avant et apres l'expression de marqueurs de predisposition
EP1506286B1 (fr) 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Anticorps anti-igfr humain neutralisant
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
WO2004042017A2 (fr) 2002-10-31 2004-05-21 Genentech, Inc. Methodes et compositions pouvant augmenter la production d'anticorps
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
WO2005021595A1 (fr) * 2003-08-28 2005-03-10 Euro-Celtique S.A. Procedes utilisant les regles des regions de presentation des anticorps pour intervenir sur des anticorps
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
EP1723970A4 (fr) * 2004-03-09 2009-08-12 Univ Kyoto Composition medicale contenant un inhibiteur medical cxcr3
DE602005025685D1 (de) 2004-12-03 2011-02-10 Schering Corp Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie
SI2292663T1 (sl) * 2006-08-28 2014-02-28 Kyowa Hakko Kirin Co., Ltd Antagonistična humana monoklonska protitelesa, specifična za humani LIGHT
GB0706070D0 (en) * 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
WO2009114585A1 (fr) * 2008-03-12 2009-09-17 Imclone Llc Anticorps de l’antigène tyrp1
JP5925116B2 (ja) * 2009-04-29 2016-05-25 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド Ｅｒｇモノクローナル抗体
CN102816240B (zh) * 2011-03-08 2014-02-12 中国人民解放军第三军医大学第二附属医院 一种融合蛋白及其融合蛋白表达载体
EP2714083A4 (fr) * 2011-05-27 2015-03-04 Fox Chase Cancer Ct Anticorps dirigés contre le récepteur de type ii d'une substance inhibitrice anti-mullérienne conçue de façon rationnelle
PL2782598T3 (pl) * 2011-11-23 2021-03-08 In3Bio Ltd. Rekombinowane białka i ich zastosowania terapeutyczne
JP5437525B1 (ja) 2012-12-28 2014-03-12 株式会社ナード研究所 チロシン誘導体およびチロシン誘導体の製造方法
EP2998322A4 (fr) * 2013-05-14 2016-12-14 Shanghai Hycharm Inc Vaccin à base d'épitopes pour protéine de faible immunogénicité et son procédé de préparation et d'utilisation
CN103275914B (zh) * 2013-06-03 2015-04-01 中国人民解放军军事医学科学院微生物流行病研究所 展示保护性抗原的细菌菌蜕及其应用
CN105263953B (zh) * 2014-01-15 2020-01-07 勃林格殷格翰动物保健美国有限公司 猪细小病毒5a、使用方法及疫苗
RU2695375C2 (ru) * 2014-05-19 2019-07-23 Вало Терапьютикс Ой Покрытые онколитические аденовирусы для противораковых вакцин
CN105693859B (zh) * 2016-03-22 2019-06-21 苏州莱泰生物科技有限公司 抗人g2a单克隆抗体以及检测人巨噬细胞g2a表达量的试剂盒
CN111978382B (zh) * 2020-09-03 2022-03-04 吉林大学第一医院 一种球形孢子丝菌Gp70重组蛋白的制备方法及其应用
CN112646029B (zh) * 2020-12-30 2022-07-29 深圳清华大学研究院 成熟脑源性神经营养因子的抗体及其应用和诊断试剂盒
CN115856296B (zh) * 2022-12-16 2023-07-25 华北理工大学 抗志贺氏菌的单克隆抗体及其检测中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011509A2 (fr) * 1992-11-16 1994-05-26 Cancer Research Fund Of Contra Costa Peptides et peptides anti-sens a large specificite neoplasique
WO1996008514A1 (fr) * 1994-09-12 1996-03-21 Tsang Kwong Y Anticorps monoclonaux diriges contre des antigenes associes au carcinome du colon humain et utilisation desdits anticorps

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69023900T4 (de) * 1989-02-24 1996-10-02 Univ California Gentechnologisch veränderte immunglobuline.
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
WO1994014848A1 (fr) * 1992-12-24 1994-07-07 The Regents Of The University Of California Immunoglobulines produites par genie genetique
WO1994014847A1 (fr) * 1992-12-24 1994-07-07 The Regents Of The University Of California Immunoglobulines produites par genie genetique
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
US5653977A (en) * 1993-09-09 1997-08-05 Uab Research Foundation Anti-idiotypic antibody that mimics the GD2 antigen
US5624904A (en) * 1993-11-17 1997-04-29 Massachusetts Institute Of Technology Method for treating gram positive septicemia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011509A2 (fr) * 1992-11-16 1994-05-26 Cancer Research Fund Of Contra Costa Peptides et peptides anti-sens a large specificite neoplasique
WO1996008514A1 (fr) * 1994-09-12 1996-03-21 Tsang Kwong Y Anticorps monoclonaux diriges contre des antigenes associes au carcinome du colon humain et utilisation desdits anticorps

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Patent evaluation: Site-specific structural modification of monoclonal antibodies for therapeutic application.", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 10, no. 2, 2000, pages 251 - 253, XP002288085 *
H. HOLZMANN ET AL.: "Assessment of the antigenic structure of tick-borne encephalitis virus by the use of synthetic peptides.", JOURNAL OF GENERAL VIROLOGY, vol. 74, no. 9, September 1993 (1993-09-01), pages 2031 - 2035, XP002287488 *
K. PROBA ET AL.: "A natural antibody missing a cysteine in VH: Consequences for thermodynamic stability and folding.", JOURNAL OF MOLECULAR BIOLOGY, vol. 265, no. 2, 17 January 1997 (1997-01-17), pages 161 - 172, XP004462317 *
L. REIDL ET AL.: "Structural basis of a conserved idiotope expressed by an autoreactive human B cell lymphoma. Evidence that a VH CDR3 mutation alters idiotypy and specificity.", THE JOURNAL OF IMMUNOLOGY, vol. 147, no. 10, 15 November 1991 (1991-11-15), BALTIMORE, MD, USA, pages 3623 - 3631, XP002287487 *
See also references of WO9925379A1 *

Also Published As

Publication number Publication date
EP1032420A1 (fr) 2000-09-06
KR20010015817A (ko) 2001-02-26
WO1999025379A1 (fr) 1999-05-27
WO1999025378A1 (fr) 1999-05-27
EP1032420A4 (fr) 2004-09-15
CA2309990A1 (fr) 1999-05-27
AU1459799A (en) 1999-06-07
CA2310269A1 (fr) 1999-05-27
WO1999025378A9 (fr) 1999-08-12
AU1459899A (en) 1999-06-07
IL136114A0 (en) 2001-05-20
CN1294517A (zh) 2001-05-09
JP2002507544A (ja) 2002-03-12
EP1030684A1 (fr) 2000-08-30
KR20010015818A (ko) 2001-02-26
AU737457B2 (en) 2001-08-23
BR9815289A (pt) 2001-12-26
AU2003252902A1 (en) 2003-11-06
BR9815580A (pt) 2002-01-29
CN1327388A (zh) 2001-12-19
JP2001526021A (ja) 2001-12-18
AU763029B2 (en) 2003-07-10
IL136113A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
IL136113A0 (en) Modified antibodies with enhanced ability to elicit an anti-idiotype response
IL136335A0 (en) Monoclonal human natural antibodies
GB9701669D0 (en) Improvements to structure
EP0973537A4 (fr) Immunogenes se liant au cocaethylene et anticorps
EP0991321A4 (fr) Tolerance a des antigenes d'anticorps naturels
ZA9948B (en) Modified antibodies with enhanced ability to elicit an anti-idiotype response.
GB9726147D0 (en) Antigens
TW312301U (en) Improved structure of earmask
TW317278U (en) Improved structure of fastener
TW341916U (en) Improved structure of date chops
GB9703276D0 (en) Materials and methods relating to the protection of useful immune cells
TW371836U (en) Structure of the multi-functional heater
TW323759U (en) Improved structure of pipeline connecting set
GB9701782D0 (en) Improvements relating to covering materials and methods
HK1038687A1 (en) Antibodies to truncated vegf-d and uses thereof
CA80435S (en) Sun shelter
TW320050U (en) Improved structure of pacifier clip
TW317745U (en) Improved structure of mini-duster
TW323471U (en) Improved structure of hairclip
TW320865U (en) Improved structure of shoe-embossing device
TW387335U (en) Improvement of net structure
TW418615U (en) Improved structure of fastener set
TW314733U (en) Structure of hairclip
TW316466U (en) Structure of hangtag
TW314988U (en) Improved structure of sensor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20040730

17Q First examination report despatched

Effective date: 20060622

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060515

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1032201

Country of ref document: HK